GMH HP 150IU Injection contains Menotrophin, a highly purified preparation of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in a 1:1 ratio, with a potency of 150 International Units (IU). It is indicated for use in the treatment of infertility in both males and females. In females, GMH HP 150IU Injection stimulates follicular development in anovulatory or oligo-ovulatory women, including those with polycystic ovary syndrome (PCOS), and is used as part of assisted reproductive technologies such as in vitro fertilization (IVF) and controlled ovarian hyperstimulation protocols. In males, it promotes spermatogenesis in cases of hypogonadotropic hypogonadism. The medication is administered via subcutaneous or intramuscular injection under medical supervision, with dosage individualized based on patient response and monitored through hormonal assays and ultrasound assessments. Adverse effects may include ovarian hyperstimulation syndrome (OHSS), injection site reactions, and multiple pregnancies. Contraindications include primary ovarian failure, uncontrolled thyroid or adrenal dysfunction, and hormone-sensitive tumors. GMH HP 150IU Injection should be used cautiously in patients with a history of hypersensitivity to gonadotropins. Proper patient selection, monitoring, and adherence to recommended dosing protocols are essential to optimize therapeutic outcomes and minimize risks.